| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 07/24/2003 | CA2471891A1 Methods of inducing or enhancing connective tissue repair |
| 07/24/2003 | CA2471744A1 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 07/24/2003 | CA2471620A1 Pyrrolidone carboxamides |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2471363A1 Albumin fusion proteins |
| 07/24/2003 | CA2470649A1 Mmp inhibitors |
| 07/24/2003 | CA2470421A1 Use of a novel cell surface protease from group b streptococcus |
| 07/23/2003 | EP1329511A1 Polypeptide having phospholipase a2 actiivty |
| 07/23/2003 | EP1329451A1 Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| 07/23/2003 | EP1328807A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 07/23/2003 | EP1328653A2 Highly expressible genes |
| 07/23/2003 | EP1328646A2 Regulation of human adenylate cyclase, type iv |
| 07/23/2003 | EP1328634A2 Genes expressed in the cell cycle |
| 07/23/2003 | EP1328624A2 B7-like molecules and uses thereof |
| 07/23/2003 | EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 07/23/2003 | EP1328539A1 Vegf peptides and their use for inhibiting angiogenesis |
| 07/23/2003 | EP1328522A2 Estrogen receptor modulators |
| 07/23/2003 | EP1328521A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 07/23/2003 | EP1328519A2 Orally active salts with tyrosine kinase activity |
| 07/23/2003 | EP1328516A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds |
| 07/23/2003 | EP1328286A1 Bone health compositions derived from milk |
| 07/23/2003 | EP1328277A1 Method for the preparation of a pharmaceutical composition, and its use |
| 07/23/2003 | EP1328272A1 Nf-kappa-b inhibitors |
| 07/23/2003 | EP1328264A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 07/23/2003 | EP1328260A2 Methods and products related to pulmonary delivery of polysaccharides |
| 07/23/2003 | EP1328254A2 Lipid formulations for target delivery |
| 07/23/2003 | EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors |
| 07/23/2003 | EP1228073B1 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 07/23/2003 | EP1183028B1 Use of certain macrolide compounds for inducing chondrogenic differentiation |
| 07/23/2003 | EP1173154A4 Chewing gum with dental benefits including calcium in a food grade acid |
| 07/23/2003 | EP1148876A4 Calcilytic compounds |
| 07/23/2003 | EP1107741B1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 07/23/2003 | EP1086096B1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 07/23/2003 | EP1032575B1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 07/23/2003 | EP1019078B1 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis |
| 07/23/2003 | EP0975636B1 1h-pyrazolo[3,4-d]pyrimidine-4,6-diones as t-cell proliferation inhibitors |
| 07/23/2003 | EP0969849B1 Stable solid preparation containing vitamin d3 and tricalcium phosphate |
| 07/23/2003 | EP0961613A4 Methods and compositions for the treatment of bone resorption disorders, including osteoporosis |
| 07/23/2003 | EP0820290B1 Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism |
| 07/23/2003 | CN1432013A Imidazole derivatives or salts thereof and drugs contg. derivatives or salts |
| 07/23/2003 | CN1432012A Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for treatment of pain |
| 07/23/2003 | CN1432011A Benzoamide piperidine compounds as substance P antagonists |
| 07/23/2003 | CN1432007A Inhibitors of alpha L beta 2 mediated cell adhesion |
| 07/23/2003 | CN1431999A Indole derivatives with vascular damagine activity |
| 07/23/2003 | CN1431998A Growth hormone secretagogues |
| 07/23/2003 | CN1431941A 挤压模 Extrusion die |
| 07/23/2003 | CN1431908A Kits and methods for optimizing efficacy of chondroprotective compsns. |
| 07/23/2003 | CN1431904A Protease inhitors |
| 07/23/2003 | CN1431204A Method for preparing water-soluble soybean aglycon and its applications |
| 07/23/2003 | CN1431009A Medicine for curing wind dampness, injuries from falls and ulcer in opening of sore |
| 07/23/2003 | CN1431003A Medicine for curing cerebral concussion and injuries from falls |
| 07/23/2003 | CN1430989A Ointment of Chinese herbal medicine for reactivating nerve and its mfg. method |
| 07/23/2003 | CN1430988A Chinese herbal medicine for treating smelly feet and its preparing method |
| 07/23/2003 | CN1430970A Application of Nano copper powder for preparing medicine for prophylaxis of osteoporosis and bone fracture |
| 07/23/2003 | CN1115165C Externally applied medicated wine for treating traumatic injury and rheumatism |
| 07/23/2003 | CN1115162C Pure traditional Chinese preparation for treating hyperosteogeny and prepn. process thereof |
| 07/23/2003 | CN1115160C Oral medicine for treating hyperosteogeny |
| 07/22/2003 | US6596900 Brain, nervous system, neurodegenerative, gastrointestinal, sleep, rheumatic, and psychological disorders; analgesics, antiepileptic agents |
| 07/22/2003 | US6596867 Bone disorders |
| 07/22/2003 | US6596772 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are |
| 07/22/2003 | US6596764 Method of preparing diacetyl rhein |
| 07/22/2003 | US6596746 Cyclic protein tyrosine kinase inhibitors |
| 07/22/2003 | US6596745 Method for treating fibrotic diseases with azolium chroman compounds |
| 07/22/2003 | US6596738 Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): |
| 07/22/2003 | US6596730 Phenyl urea and phenyl thiourea derivatives |
| 07/22/2003 | US6596721 (6S)- or 10 (6R,S)- tetrahydrofolic acid is crystallized in a polar medium with pH of 3.5 or greater and have a purity 98% |
| 07/22/2003 | US6596715 Protease inhibitors |
| 07/22/2003 | US6596687 Cell adhesion inhibitors |
| 07/22/2003 | US6596498 Bone stimulating factor |
| 07/22/2003 | US6596303 Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| 07/22/2003 | CA2294422C Tartrate salt of a substituted dipeptide |
| 07/21/2003 | CA2416791A1 A receptor-ligand pairing for immune response |
| 07/21/2003 | CA2368656A1 Receptor-ligand pairing for anti-inflammatory response |
| 07/17/2003 | WO2003058021A2 Novel apoptosis-inducing dna sequences |
| 07/17/2003 | WO2003057856A2 Dominant negative proteins and methods thereof |
| 07/17/2003 | WO2003057854A2 Novel proteins and nucleic acids encoding same |
| 07/17/2003 | WO2003057733A1 Antibodies against fibroblast growth factor 23 |
| 07/17/2003 | WO2003057729A2 Mammal prolactin variants |
| 07/17/2003 | WO2003057699A1 Dibenzodiazepine derivates, their preparation and use |
| 07/17/2003 | WO2003057696A1 Deazapurines and uses thereof |
| 07/17/2003 | WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | WO2003057668A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use |
| 07/17/2003 | WO2003057666A2 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057252A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | WO2003057251A1 Remedies for arthritis |
| 07/17/2003 | WO2003057225A2 Phosphate transport inhibitors |
| 07/17/2003 | WO2003057219A1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 07/17/2003 | WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases. |
| 07/17/2003 | WO2003057202A1 Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
| 07/17/2003 | WO2003057201A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | WO2003057149A2 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| 07/17/2003 | WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/17/2003 | WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057136A2 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | WO2003057134A2 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | WO2003057133A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002029060A9 Hematopoietin receptors hpr1 and hpr2 |